Wolf Group Capital Advisors Sells 1,509 Shares of Cencora, Inc. (NYSE:COR)

Wolf Group Capital Advisors reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 15.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,999 shares of the company's stock after selling 1,509 shares during the period. Wolf Group Capital Advisors' holdings in Cencora were worth $2,224,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. lifted its holdings in Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after purchasing an additional 1,995 shares during the last quarter. Westpac Banking Corp lifted its holdings in Cencora by 13.5% during the 4th quarter. Westpac Banking Corp now owns 21,895 shares of the company's stock valued at $4,919,000 after purchasing an additional 2,596 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Cencora by 3.3% during the 4th quarter. CIBC Asset Management Inc now owns 40,542 shares of the company's stock valued at $9,101,000 after purchasing an additional 1,305 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. lifted its holdings in Cencora by 5.2% during the 4th quarter. Leith Wheeler Investment Counsel Ltd. now owns 82,952 shares of the company's stock valued at $18,638,000 after purchasing an additional 4,126 shares during the last quarter. Finally, Atlas Legacy Advisors LLC bought a new position in Cencora during the 4th quarter valued at about $930,000. 97.52% of the stock is owned by institutional investors.

Cencora Trading Up 1.3%

Shares of NYSE:COR traded up $3.72 during trading on Thursday, hitting $296.92. 1,167,452 shares of the company's stock were exchanged, compared to its average volume of 1,526,132. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm has a 50-day moving average price of $288.80 and a two-hundred day moving average price of $262.88. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The firm has a market cap of $57.55 billion, a P/E ratio of 34.44, a PEG ratio of 1.47 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the previous year, the company earned $3.80 EPS. Cencora's revenue was up 10.3% on a year-over-year basis. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,253 shares of company stock worth $10,582,297. 10.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on COR. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. UBS Group raised their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Citigroup raised their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, Bank of America raised their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.